The role and efficacy of Vandetanib

Given its manageable adverse event profile, Vandetanib is a reasonable treatment option for patients with advanced medullary thyroid cancer. Vandetanib is recommended for patients with symptomatic or developing metastatic, recurrent, or persistent disease, and treatment should be continued until disease progression or intolerable treatment toxicity. Asymptomatic patients with detectable elevations in laboratory markers such as calcitonin or CEA should not be initiated on vandetanib.

In a major study, vandetanib was more effective in adults with medullary thyroid cancer that cannot be removed with surgery or has spread to other parts of the body. The study involved 331 patients, and the main measure of effectiveness was progression-free survival (how long patients lived without their disease getting worse). On average, patients taking vandetanib lived 30.5 months without worsening of their disease. In a second major study, vandetanib was used in children aged 9 to 17 years with hereditary medullary thyroid cancer. The main measure of effectiveness is the "overall response rate" (ORR), which takes into account several characteristics of the disease. Of the 16 children treated with vandetanib, 7 (44%) had a partial response on the ORR scale, which is comparable to response rates in adults. Children taking vandetanib survived an average of 46 months without disease progression.

The original drug vandetanib has not yet been marketed in China, so it is not included in medical insurance. The original drug specifications of vandetanib listed overseasThe price of each box of 300mg*30 tablets may be more than 30,000 yuan (the price may fluctuate due to the exchange rate). There is currently no generic drug of vandetanib produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.